RCUS Arcus Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RCUS

Price (delayed)

$15.83

Market cap

$1.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.15

Enterprise value

$1.31B

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. ...

Highlights
RCUS's revenue is up by 4.5% YoY but it is down by 2.5% QoQ
The gross profit has grown by 4.5% YoY but it has contracted by 2.5% from the previous quarter
RCUS's equity is down by 30% year-on-year and by 11% since the previous quarter
RCUS's quick ratio is down by 20% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcusbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RCUS
Market
Shares outstanding
90.86M
Market cap
$1.44B
Enterprise value
$1.31B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.56
Price to sales (P/S)
10.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.21
Earnings
Revenue
$117M
EBIT
-$301M
EBITDA
-$285M
Free cash flow
-$330M
Per share
EPS
-$4.15
Free cash flow per share
-$4.46
Book value per share
$6.17
Revenue per share
$1.58
TBVPS
$14.8
Balance sheet
Total assets
$1.1B
Total liabilities
$633M
Debt
$0
Equity
$462M
Working capital
$647M
Liquidity
Debt to equity
0
Current ratio
4.52
Quick ratio
4.33
Net debt/EBITDA
0.45
Margins
EBITDA margin
-243.6%
Gross margin
100%
Net margin
-262.4%
Operating margin
-290.6%
Efficiency
Return on assets
-25.8%
Return on equity
-57.2%
Return on invested capital
-37.2%
Return on capital employed
-33%
Return on sales
-257.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RCUS stock price

How has the Arcus Biosciences stock price performed over time
Intraday
2.13%
1 week
1.8%
1 month
-10.51%
1 year
-14.71%
YTD
-17.12%
QTD
-16.15%

Financial performance

How have Arcus Biosciences's revenue and profit performed over time
Revenue
$117M
Gross profit
$117M
Operating income
-$340M
Net income
-$307M
Gross margin
100%
Net margin
-262.4%
Arcus Biosciences's operating income has decreased by 21% YoY and by 5% from the previous quarter
The operating margin has declined by 16% year-on-year and by 8% since the previous quarter
The net income is down by 15% year-on-year and by 4.8% since the previous quarter
Arcus Biosciences's net margin has decreased by 10% YoY and by 7% from the previous quarter

Growth

What is Arcus Biosciences's growth rate over time

Valuation

What is Arcus Biosciences stock price valuation
P/E
N/A
P/B
2.56
P/S
10.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.21
RCUS's EPS is down by 12% year-on-year and by 3.8% since the previous quarter
RCUS's equity is down by 30% year-on-year and by 11% since the previous quarter
RCUS's price to book (P/B) is 13% lower than its 5-year quarterly average of 2.9 and 3.5% lower than its last 4 quarters average of 2.6
RCUS's P/S is 60% below its 5-year quarterly average of 24.6 and 16% below its last 4 quarters average of 11.7
RCUS's revenue is up by 4.5% YoY but it is down by 2.5% QoQ

Efficiency

How efficient is Arcus Biosciences business performance
The return on equity has dropped by 55% year-on-year and by 14% since the previous quarter
RCUS's ROIC is down by 46% YoY and by 10% from the previous quarter
Arcus Biosciences's return on assets has decreased by 39% YoY and by 10% QoQ
RCUS's return on sales is down by 8% year-on-year and by 7% since the previous quarter

Dividends

What is RCUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCUS.

Financial health

How did Arcus Biosciences financials performed over time
The total assets is 73% greater than the total liabilities
RCUS's quick ratio is down by 20% year-on-year
The total assets has declined by 19% year-on-year and by 8% since the previous quarter
Arcus Biosciences's debt is 100% less than its equity
RCUS's equity is down by 30% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.